AVF2107

Regimen

Experimental
Bevacizumab 5 mg/kg Q2W + IFL (bolus irinotecan + 5-FU/LV)
Control
Placebo + IFL (bolus irinotecan + 5-FU/LV)

Population

Metastatic CRC, 1L, previously untreated; all-comers regardless of RAS status.

Key finding

1L mCRC (unselected): mOS 20.3 vs 15.6 mo (HR 0.66, p<0.001); mPFS 10.6 vs 6.2 mo (HR 0.54, p<0.001); ORR 44.8% vs 34.8% (p=0.004); response duration 10.4 vs 7.1 mo; grade 3 hypertension 11.0% vs 2.3%

Source: PMID 15175435

Timeline

    Guideline citations

    • NCCN Colon (p.60)
    • NCCN Rectal (p.77)